Orsini Chosen as the Exclusive Specialty Pharmacy Provider for MIPLYFFA™ (arimoclomol), the First FDA-Approved Treatment for Niemann-Pick Disease Type C – StreetInsider.com

Orsini Chosen as the Exclusive Specialty Pharmacy Provider for MIPLYFFA™ (arimoclomol), the First FDA-Approved Treatment for Niemann-Pick Disease Type C  StreetInsider.com
Read More…

Source: https://www.streetinsider.com/PRNewswire/Orsini+Chosen+as+the+Exclusive+Specialty+Pharmacy+Provider+for+MIPLYFFA%E2%84%A2+%28arimoclomol%29%2C+the+First+FDA-Approved+Treatment+for+Niemann-Pick+Disease+Type+C/23753955.html